ECSP045425A - COMPUESTOS HETEROCÍCLICOS QUE INHIBEN LA ADHESIÓN DE LEUCOCITOS MEDIADA POR INTEGRINAS a4 - Google Patents

COMPUESTOS HETEROCÍCLICOS QUE INHIBEN LA ADHESIÓN DE LEUCOCITOS MEDIADA POR INTEGRINAS a4

Info

Publication number
ECSP045425A
ECSP045425A EC2004005425A ECSP045425A ECSP045425A EC SP045425 A ECSP045425 A EC SP045425A EC 2004005425 A EC2004005425 A EC 2004005425A EC SP045425 A ECSP045425 A EC SP045425A EC SP045425 A ECSP045425 A EC SP045425A
Authority
EC
Ecuador
Prior art keywords
compounds
sub
integrins
inhibit
leukocytes
Prior art date
Application number
EC2004005425A
Other languages
English (en)
Inventor
Andrei Konradi
Christopher M Semko
Ying-Zi Xu
Frank Stappenbeck
Brian P Stupi
Jenifer Smith
Eugene D Thorsett
Michael A Pleiss
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of ECSP045425A publication Critical patent/ECSP045425A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos que se unen a las integrinas a4, con preferencia VLA-4. Algunos de estos compuestos también pueden inhibir la adhesión de leucocitos y, en particular, adhesión de leucocitos mediada por las integrinas a4, con preferencia VLA-4. Dichos compuestos son útiles en el tratamiento de enfermedades inflamatorias en un paciente mamífero, por ejemplo, humano, como asma, enfermedad de Alzheimer, ateroesclerosis, demencia producida por el SIDA, diabetes, enfermedad inflamatoria de intestinos, artritis reumatoide, transplante de tejidos, metástasis de tumores e isquemia de miocardio. Los compuestos también pueden administrarse para el tratamiento de enfermedades inflamatorias del cerebro como la esclerosis múltiple.
EC2004005425A 2002-05-24 2004-10-11 COMPUESTOS HETEROCÍCLICOS QUE INHIBEN LA ADHESIÓN DE LEUCOCITOS MEDIADA POR INTEGRINAS a4 ECSP045425A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38302002P 2002-05-24 2002-05-24

Publications (1)

Publication Number Publication Date
ECSP045425A true ECSP045425A (es) 2005-03-10

Family

ID=29584493

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005425A ECSP045425A (es) 2002-05-24 2004-10-11 COMPUESTOS HETEROCÍCLICOS QUE INHIBEN LA ADHESIÓN DE LEUCOCITOS MEDIADA POR INTEGRINAS a4

Country Status (23)

Country Link
US (3) US7135477B2 (es)
EP (1) EP1507775B1 (es)
JP (1) JP4469715B2 (es)
KR (1) KR100978832B1 (es)
CN (1) CN1314682C (es)
AT (1) ATE419243T1 (es)
AU (1) AU2003240823C1 (es)
BR (1) BR0308881A (es)
CA (1) CA2481926C (es)
DE (1) DE60325583D1 (es)
DK (1) DK1507775T3 (es)
EA (1) EA008256B1 (es)
EC (1) ECSP045425A (es)
ES (1) ES2320436T3 (es)
HK (1) HK1072608A1 (es)
IL (2) IL164225A0 (es)
MX (1) MXPA04010995A (es)
NO (1) NO329933B1 (es)
NZ (1) NZ535504A (es)
TW (1) TWI281470B (es)
UA (1) UA76339C2 (es)
WO (1) WO2003099809A1 (es)
ZA (1) ZA200407590B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100711840B1 (ko) * 1999-01-22 2007-05-02 엘란 파마슈티칼스, 인크. Ｖｌａ-4 관련 질환 치료용 아실 유도체
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
EP1635822A4 (en) * 2003-06-25 2009-06-24 Elan Pharm Inc METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS
WO2005111020A2 (en) * 2004-04-30 2005-11-24 Elan Pharmaceuticals, Inc. Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4
JP2008505927A (ja) * 2004-07-08 2008-02-28 イーラン ファーマスーティカルズ、インコーポレイテッド ポリマー部分を含む多価ｖｌａ−４拮抗薬
EP1881982B1 (en) * 2005-05-20 2013-11-20 Elan Pharmaceuticals Inc. Imidazolone phenylalanine derivatives as vla-4 antagonists
ZA200803016B (en) * 2005-09-29 2009-10-28 Elan Pharmaceuticals Inc Wyeth Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
EA015388B1 (ru) * 2005-09-29 2011-08-30 Элан Фамэсьютикэлс, Инк. ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ
MY151045A (en) 2006-02-27 2014-03-31 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
WO2007100770A2 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007100763A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
WO2007103112A2 (en) * 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US8269009B2 (en) 2007-12-07 2012-09-18 Elan Pharmaceuticals, Inc. Methods and compositions for treating liquid tumors
EP2085407A1 (en) 2008-02-04 2009-08-05 Sahltech I Göteborg AB Treatment of idiopathic thrombocytopenic purpura
RU2010141964A (ru) * 2008-04-29 2012-06-10 НСАБ, Филиаль аф НьюроСерч Свиден АБ, Сверийе (DK) Модуляторы дофаминовой нейротрансмиссии
CN102459179A (zh) * 2009-04-27 2012-05-16 艾伦药物公司 α-4整联蛋白的吡啶酮拮抗剂
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PT2524060T (pt) 2010-01-11 2018-03-28 Biogen Ma Inc Ensaio para a deteção de anticorpos contra o vírus jc
RS63989B1 (sr) 2011-05-31 2023-03-31 Biogen Ma Inc Postupak evaluacije rizika za pml
JP6080521B2 (ja) * 2012-11-30 2017-02-15 インターナショナル・ビジネス・マシーンズ・コーポレーションＩｎｔｅｒｎａｔｉｏｎａｌ Ｂｕｓｉｎｅｓｓ Ｍａｃｈｉｎｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 広域分散医療情報ネットワークのデータ管理機構
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML
EP3294716B1 (en) * 2015-12-30 2020-04-15 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
SG11202103484RA (en) 2018-10-30 2021-05-28 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
CN109541237A (zh) * 2018-12-28 2019-03-29 吴江近岸蛋白质科技有限公司 纤维连接蛋白的生物学活性测定方法
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2525656A1 (de) 1974-06-19 1976-01-15 Sandoz Ag Verfahren zur herstellung neuer heterocyclischer verbindungen
US4096255A (en) * 1974-11-08 1978-06-20 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods
US4018915A (en) 1976-01-05 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4046876A (en) 1974-11-08 1977-09-06 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4041156A (en) * 1974-11-08 1977-08-09 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4104392A (en) * 1974-11-08 1978-08-01 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them
US4070457A (en) * 1974-11-08 1978-01-24 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4055636A (en) 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4073914A (en) 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4055651A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
JPS5727454B2 (es) * 1975-02-21 1982-06-10
US4036955A (en) * 1976-07-22 1977-07-19 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
CA1102316A (en) 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
US4018913A (en) * 1976-01-14 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
DE2742173A1 (de) * 1977-09-20 1979-03-29 Bayer Ag Phenoxy-pyridinyl(pyrimidinyl)-alkanole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IT1211096B (it) 1981-08-20 1989-09-29 Lpb Ist Farm Pirimidine e s.triazinici adattivita' ipolipidemizzante.
US4672065A (en) * 1982-11-19 1987-06-09 Chevron Research Company N-substituted phenoxyacetamide fungicides
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
CA1218655A (en) 1983-01-28 1987-03-03 Kathleen Biziere Process for the preparation of pyridazine derivatives having a psychotropic action
JPS59212480A (ja) 1983-05-17 1984-12-01 Nippon Soda Co Ltd ピリダジン誘導体及び除草剤
DE3322720A1 (de) * 1983-06-24 1985-01-03 Chemische Werke Hüls AG, 4370 Marl Verwendung von in 2-stellung mit (substituierten) aminogruppen substituierten 4-dl-alkylester-(alpha)-alaninyl-6-chlor-s-triazinen als herbizide, insbesondere gegen flughafer
US4505910A (en) * 1983-06-30 1985-03-19 American Home Products Corporation Amino-pyrimidine derivatives, compositions and use
NZ210669A (en) 1983-12-27 1988-05-30 Syntex Inc Benzoxazin-4-one derivatives and pharmaceutical compositions
US4595364A (en) * 1984-02-15 1986-06-17 Molten Corp. Dental prosthesis and process for preparing the same
PH22520A (en) 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
US4959364A (en) 1985-02-04 1990-09-25 G. D. Searle & Co. Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH0784424B2 (ja) 1987-04-15 1995-09-13 味の素株式会社 チロシン誘導体及びその用途
EP0330506A3 (en) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
DE3904931A1 (de) 1989-02-17 1990-08-23 Bayer Ag Pyridyl-substituierte acrylsaeureester
US5030644A (en) * 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US4992439A (en) * 1990-02-13 1991-02-12 Bristol-Myers Squibb Company Pyridazine carboxylic acids and esters
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
DE4108029A1 (de) * 1991-03-13 1992-09-17 Bayer Ag Triazinyl-substituierte acrylsaeureester
WO1992016549A1 (de) 1991-03-18 1992-10-01 Pentapharm Ag Para-substituierte phenylalanin-derivate
IT1247509B (it) 1991-04-19 1994-12-17 Univ Cagliari Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
AU3420693A (en) 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
EP0633881B1 (en) 1992-03-11 2003-10-29 Narhex Limited Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
DE4227748A1 (de) * 1992-08-21 1994-02-24 Bayer Ag Pyridyloxy-acrylsäureester
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
CA2193508A1 (en) 1994-07-11 1996-01-25 Eugene D. Thorsett Inhibitors of leukocyte adhesion
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
CA2230209A1 (en) * 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
HU225226B1 (en) 1995-09-29 2006-08-28 Sankyo Lifetech Company Ltd 13-substituted milbemycin 5-oxime derivatives, their use, and anthelmintic, acaricide and insecticide compositions containing these compounds
DE19536891A1 (de) 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
DK0910575T3 (da) 1996-06-21 2003-02-03 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af peptider
CZ424998A3 (cs) 1996-06-28 1999-03-17 Merck Patent Gmbh Deriváty fenylaminu jakožto integrinové inhibitory
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19647317A1 (de) 1996-11-15 1998-05-20 Hoechst Schering Agrevo Gmbh Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
HUP0000492A3 (en) 1996-11-22 2000-06-28 Lilly Co Eli N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
AU6264898A (en) 1997-02-04 1998-08-25 Versicor Inc Solid phase and combinatorial library syntheses of 3,1-benzoxazine-4-ones
DE19713000A1 (de) 1997-03-27 1998-10-01 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
JP2002512625A (ja) 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
JP2001517245A (ja) 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
CN1265669A (zh) 1997-07-31 2000-09-06 伊兰药品公司 抑制由vla－4介导的白细胞粘着的化合物
CN1133648C (zh) 1997-07-31 2004-01-07 伊兰药品公司 抑制vla-4介导的白细胞粘附的取代的苯丙氨酸型化合物
EP1001971A1 (en) 1997-07-31 2000-05-24 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
EP1005446B1 (en) 1997-08-22 2004-02-25 F. Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
DK1005445T3 (da) 1997-08-22 2004-10-04 Hoffmann La Roche N-alkanoylphenylaninderivater
JP4564654B2 (ja) 1998-01-23 2010-10-20 ノバルティス アーゲー Ｖｌａ−４アンタゴニスト
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
NZ507534A (en) 1998-04-16 2002-02-01 Texas Biotechnology Corp N,N-disubstituted amide substituted propanoic acid derivatives useful for inhibiting the binding of intergrins to their receptors
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
KR100711840B1 (ko) * 1999-01-22 2007-05-02 엘란 파마슈티칼스, 인크. Ｖｌａ-4 관련 질환 치료용 아실 유도체
WO2000043369A1 (en) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
PE20020384A1 (es) 2000-07-21 2002-05-28 Schering Corp PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins

Also Published As

Publication number Publication date
CN1656090A (zh) 2005-08-17
US20040138243A1 (en) 2004-07-15
CA2481926C (en) 2012-04-24
US7135477B2 (en) 2006-11-14
IL164225A (en) 2010-11-30
MXPA04010995A (es) 2005-09-08
IL164225A0 (en) 2005-12-18
HK1072608A1 (en) 2005-09-02
KR20050003434A (ko) 2005-01-10
US20050119290A1 (en) 2005-06-02
ZA200407590B (en) 2006-10-25
EP1507775A4 (en) 2006-05-24
AU2003240823B2 (en) 2008-11-06
CA2481926A1 (en) 2003-12-04
ATE419243T1 (de) 2009-01-15
NO329933B1 (no) 2011-01-24
AU2003240823A1 (en) 2003-12-12
JP2005527628A (ja) 2005-09-15
TWI281470B (en) 2007-05-21
US7427628B2 (en) 2008-09-23
JP4469715B2 (ja) 2010-05-26
EA200401562A1 (ru) 2005-06-30
US20070027131A1 (en) 2007-02-01
TW200400946A (en) 2004-01-16
ES2320436T3 (es) 2009-05-22
UA76339C2 (en) 2006-07-17
NO20043900L (no) 2004-11-10
BR0308881A (pt) 2005-01-11
EA008256B1 (ru) 2007-04-27
KR100978832B1 (ko) 2010-08-30
US7026328B2 (en) 2006-04-11
AU2003240823C1 (en) 2009-05-28
NZ535504A (en) 2005-11-25
DE60325583D1 (de) 2009-02-12
CN1314682C (zh) 2007-05-09
DK1507775T3 (da) 2009-05-11
EP1507775B1 (en) 2008-12-31
EP1507775A1 (en) 2005-02-23
WO2003099809A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
ECSP045425A (es) COMPUESTOS HETEROCÍCLICOS QUE INHIBEN LA ADHESIÓN DE LEUCOCITOS MEDIADA POR INTEGRINAS a4
EA200401561A1 (ru) Гетероарильные соединения, которые ингибируют опосредованную 4-интегринами адгезию лейкоцитов
TW200603788A (en) Multivalent vla-4 antagonists comprising polymer moieties
DK1940826T3 (da) Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4
MXPA01007335A (es) Derivados de acilo los cuales tratan trastornos relacionados con alfa4 beta1 integrina y cd49d/cd29 (vla-4).
MY151045A (en) Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
NO20000451L (no) Forbindelser som inhiberer leukocyttadhesjon mediert av VLA-4
NO20000412L (no) Dipeptidforbindelser som inhiberer leukocytt-adhesjon mediert av VLA-4
NO20000414L (no) Benzylforbindelser som inhiberer leukocytt adhesjon mediert av VLA-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
ATE264298T1 (de) Alpha-aminoessigsäure derivate als alpha 4 beta 7-rezeptor antagonisten
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4